NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population



Título del documento: NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population
Revista: Annals of hepatology
Base de datos: PERIÓDICA
Número de sistema: 000419063
ISSN: 1665-2681
Autores: 1
1
2
1
1
1
3
4
5
6
7
1
1
1
Instituciones: 1Peking University Health Science Center, School of Public Health, Beijing. China
2National Center for Tuberculosis Control and Prevention, Department of Surveillance and Statistics, Beijing. China
3Peking University Cancer Hospital, Department of Medical Imaging, Beijing. China
4Beijing Institute for Tuberculosis Control, Department of Outpatient, Beijing. China
5State Food and Drug Administration, Center for Drug Reassessment, Beijing. China
6Beijing Drug Administration, Center for Drug Reassessment, Beijing. China
7Beijing Tuberculosis and Thoracic Tumor Research Institute, Department of Tuberculosis Treatment, Beijing. China
Año:
Periodo: Sep-Oct
Volumen: 11
Número: 5
Paginación: 700-707
País: México
Idioma: Inglés
Tipo de documento: Artículo
Enfoque: Analítico, descriptivo
Resumen en inglés Anti-tuberculosis drug-induced hepatotoxicity (ATDH) is one of the most prevalent and serious adverse drug reactions in the course of anti-tuberculosis (TB) treatment. Some researchers suggested that determination of N-acetyltransferase 2 (NAT2) genotype may be clinically useful to identify patients at high risk of developing ATDH. Aim. To evaluate whether the NAT2 genotype could be as a predictor for ATDH in Chinese community TB population. Material and methods. A total of 4304 community-based TB patients were followed up six to nine months prospectively. A nested case-control study was designed. Each ATDH case was 1:4 matched with controls by age (within 5 years old), gender, treatment history, disease severity and drug dosage. The polymorphisms of NAT2 were determined using polymerase chain reaction with restriction fragment length polymorphism. Conditional Logistic regression model was used to calculate odds ratio (OR) and 95% confidence interval (CI), as well as corresponding P-values. Results. A total of 89 ATDH cases and 356 controls were included in this study. Allele frequency of NAT2*5, NAT2*6 and NAT2*7 in cases and controls were 4.5 and 3.2%, 25.3 and 26.5%, and 13.5 and 13.5%, respectively. Frequencies of genotypes and alleles of NAT2*5, NAT2*6 and NAT2*7 did not differ significantly between cases and controls. The OR of intermediate acetylator and slow acetylator compared with rapid acetylator was 1.040 (95%CI 0.616-1.758) and 0.990 (95%CI 0.509-1.925), respectively. The NAT2 haplotype distribution in cases was similar to controls. Conclusions. In conclusion, we did not find significant association between NAT2 genotype and ATDH in community-based Chinese population. It may be deficient to take NAT2 genotype as a predictor for ATDH in Chinese community TB patients
Disciplinas: Medicina
Palabras clave: Gastroenterología,
Farmacología,
Fármacos antituberculosos,
Hepatotoxicidad,
Polimorfismo genético
Keyword: Gastroenterology,
Pharmacology,
Antituberculosis agents,
Hepatotoxicity,
Genetic polymorphism
Texto completo: Texto completo (Ver PDF)